News for Recursion Pharmaceuticals, Inc. (RXRX)

You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.

U.S. stock market futures are treading water this morning as investors wait for major earnings from Microsoft, Tesla, and Alphabet. After a hot rally, Wall Street is pausing, watching rising Treasury yields and trade tensions closely. While Dow, S&P 500, and Nasdaq futures are slightly down, sharp moves in individual stocks are stirring interest. Some small-cap names are flying, while others tumble. This is shaping up to be a high-stakes week, and the markets could turn quickly.

U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Monday. Shares of Galaxy Digital GLXY rose sharply during Monday's session after...

When it comes to Nvidia-backed data center stocks, investors can't get enough of CoreWeave. Another competing force is emerging in the background, though.

Recursion Pharmaceuticals (RXRX) is experiencing significant bullish activity in the options market. A total of 7,175 call options have been traded, aligning cl

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley assumed coverage of the company’s stock with an “Equal Weight” rating and a price objective of $5, as reported by The Fly. As per the analyst, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock witnessed volatility because of a combination of […]

Recursion Pharmaceuticals bounced back by 8.72 percent on Tuesday to close at $5.36 apiece following news that it acquired a $25-million interest in REV102—an ENPP1 inhibitor in preclinical development...

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia, to joint venture partner Recursion Pharmaceuticals (RXRX) for up to $25M, including an upfront equity payment of $7.5M and near term milestones. With the upfront payment, Rallybio expects its cash runway to extend into mid-2027. The REV102 program originated from a joint venture between Rallybi

U.S. markets showed signs of recovery on Tuesday, July 8, 2025, as investors regained some confidence following Monday's steep sell-off triggered by President

According to Recursion Pharmaceuticals, Inc.

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach to drug discovery driven by AI and machine...

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.27, denoting a +1.15% move from the preceding trading day.

In a recent update, Morgan Stanley analyst Vikram Purohit has initiated coverage on Recursion Pharmaceuticals (RXRX), announcing a price target of USD 5.00. The

Recursion Pharmaceuticals (RXRX), operating on the NASDAQ, is under the spotlight following recent analyst action from Morgan Stanley. Analyst Vikram Purohit ha

Morgan Stanley has adjusted its price target for Recursion Pharmaceuticals (RXRX), reducing it from $8 to $5. The financial services firm maintains an Equal Wei

The U.S. stock market ended Friday, June 6, 2025, with substantial gains across all major indexes, as investors responded positively to better-than-expected

The U.S. stock market rallied strongly on Friday, June 6, 2025, with the S&P 500 breaking above the 6,000 level for the first time since February. As of

PR NewswireVANCOUVER, BC, June 4, 2025 Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc.VANCOUVER, BC, June 4, 2025 /PRNewswire/ --